0QAV Stock Chart & Stats
€28.82
-€0.07(-2.36%)
At close: 4:00 PM EST
€28.82
-€0.07(-2.36%)
Day’s Range― - ―
52-Week Range€13.12 - €47.60
Previous CloseN/A
Volume19.00
Average Volume (3M)11.87K
Market Cap
€1.04B
Enterprise Value€1.56B
Total Cash (Recent Filing)€110.89M
Total Debt (Recent Filing)€106.61M
Price to Earnings (P/E)―
Beta0.89
Next Earnings
Apr 27, 2027EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend Yield4.6%
Share Statistics
EPS (TTM)-1.10
Shares Outstanding50,825,684
10 Day Avg. Volume14,536
30 Day Avg. Volume11,867
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)-10.94
Price to Sales (P/S)31.19
P/FCF Ratio-27.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€60.00Price Target Upside108.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.39
Revenue Forecast (FY)€21.56M
Bulls Say, Bears Say
Bulls Say
Oncology Platform BreadthThe NBTXR3 platform addresses a broad oncology opportunity by aiming to improve radiotherapy-driven tumor destruction across multiple solid tumor indications. If clinical development succeeds, one technology could support several applications and create scalable strategic value.
2025 Revenue GrowthSharp revenue growth in 2025 indicates that the company has demonstrated some ability to expand its reported top line despite earlier volatility. Continued progress could improve operating leverage and provide a stronger commercial foundation if growth becomes repeatable.
Gross Margin PotentialA 100% gross margin in 2025 suggests reported revenue carried no corresponding cost of goods burden in that period. This indicates potentially attractive economics at the gross-profit level, although durable value still depends on converting that margin into operating profitability.
Bears Say
Persistent UnprofitabilityPersistent operating and net losses show that the business has not yet established sustainable earnings power. Continued losses can absorb capital, reduce financial resilience, and make future progress dependent on successful development and eventual improvement in operating results.
Ongoing Cash BurnConsistently negative operating and free cash flow means reported activity is not yet generating internal funding. Because free cash flow broadly tracks net losses, the company may need continued external financing to sustain development and support operations over the coming quarters.
Negative Equity And Rising DebtNegative shareholders’ equity materially weakens financial flexibility, while rising debt increases leverage pressure against that limited capital base. This combination heightens dependence on external funding and reduces the company’s ability to absorb setbacks or finance growth independently.
0QAV FAQ
What was Nanobiotix SA’s price range in the past 12 months?
Nanobiotix SA lowest share price was €13.12 and its highest was €47.60 in the past 12 months.
What is Nanobiotix SA’s market cap?
Nanobiotix SA’s market cap is €1.04B.
When is Nanobiotix SA’s upcoming earnings report date?
Nanobiotix SA’s upcoming earnings report date is Apr 27, 2027 which is in 199 days.
How were Nanobiotix SA’s earnings last quarter?
Nanobiotix SA released its earnings results on Sep 24, 2026. The company reported -€0.7 earnings per share for the quarter, missing the consensus estimate of -€0.25 by -€0.45.
Is Nanobiotix SA overvalued?
According to Wall Street analysts Nanobiotix SA’s price is currently Undervalued.
Does Nanobiotix SA pay dividends?
Nanobiotix SA pays a Notavailable dividend of €0.285 which represents an annual dividend yield of 4.6%. See more information on Nanobiotix SA dividends here
What is Nanobiotix SA’s EPS estimate?
Nanobiotix SA’s EPS estimate is 0.05.
How many shares outstanding does Nanobiotix SA have?
Nanobiotix SA has 50,825,684 shares outstanding.
What happened to Nanobiotix SA’s price movement after its last earnings report?
Nanobiotix SA reported an EPS of -€0.7 in its last earnings report, missing expectations of -€0.25. Following the earnings report the stock price went up 4.196%.
Which hedge fund is a major shareholder of Nanobiotix SA?
Currently, no hedge funds are holding shares in GB:0QAV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nanobiotix SA
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
0QAV Stock 12 Month Forecast
Average Price Target
€60.00
▲(108.19% Upside)
Technical Analysis
Innate Pharma SA
―
Transgene
―
OSE Immunotherapeutics SA
―
Cellectis SA
―
MaaT Pharma
―